Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining

被引:5
|
作者
Hashimoto, Takafumi [1 ]
Osoegawa, Atsushi [1 ]
Takumi, Yohei [1 ]
Abe, Miyuki [1 ]
Kobayashi, Ryoji [1 ]
Miyawaki, Michiyo [1 ]
Takeuchi, Hideya [1 ]
Okamoto, Tatsuro [1 ]
Sugio, Kenji [1 ]
机构
[1] Oita Univ, Fac Med, Dept Thorac & Breast Surg, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan
关键词
Lung cancer; Intratumoral heterogeneity; Epidermal growth factor receptor; Immunohistochemistry; Copy number variation; MUTATION-SPECIFIC ANTIBODIES; ACQUIRED-RESISTANCE; EGFR MUTATION; 1ST-LINE TREATMENT; OPEN-LABEL; MESENCHYMAL TRANSITION; TUMOR HETEROGENEITY; GENETIC ALTERATIONS; EVOLUTION; GEFITINIB;
D O I
10.1016/j.lungcan.2018.08.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although intratumoral heterogeneity is commonly observed in several cancers, few studies have shown its presence in EGFR-mutated lung cancer. We performed immunohistochemistry to analyze the intratumoral heterogeneity in EGFR-mutated (L858R) lung cancer and performed targeted sequencing in specific cases. We discuss the effects of intratumoral heterogeneity and acquired resistance to EGFR-TKI. Methods: Twenty resected primary lung cancers known to harbor EGFR L858R were analyzed. IHC was performed using an L858R mutant-specific rabbit monoclonal antibody and the samples were scored by staining intensity (0-3) and proportion. For cases with heterogeneous L858R protein expression, the nucleic acids were extracted from each differently stained lesion, and targeted sequencing was performed. Single nucleotide variations (SNVs) and copy number variations (CNVs) were then analyzed. The cell proliferation and apoptosis were also evaluated by the ki-67 labeling index and TUNEL staining. Results: Among 20 cases, 3 showed heterogeneous staining. Genetic analyses for cases with heterogeneous staining revealed an increase in the copy number of EGFR in the IHC-positive part compared to the negative part, and an increase in the copy number of CCNE1 was observed in the IHC-positive part compared to the negative part in one case (case 1). In another case (case 2), an increase in the copy number of EGFR was observed in the IHC-positive part compared to the negative part, and an increase in the copy number of MDM2 was observed in the IHC-positive part compared to the negative part. In three cases, no SNV changes were observed. An increase in the ki-67 labeling index in the L858R-positive part in case 1 and increased apoptosis in the L858R-positive part in case 2 were observed, suggesting the functional significance of CNV changes. Conclusion: These cases exhibiting L858R IHC intratumoral heterogeneity suggest a heterogeneous effect on the cell activity due to CNV heterogeneity.
引用
收藏
页码:241 / 247
页数:7
相关论文
共 50 条
  • [1] Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?
    Davies, Rhian Sian
    Nelmes, Daniel John
    Butler, Rachel
    Lester, Jason Francis
    ANTICANCER RESEARCH, 2016, 36 (08) : 4267 - 4271
  • [2] Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution
    Koyama, Nobuyuki
    Watanabe, Yasutaka
    Iwai, Yuki
    Kawamura, Rumi
    Miwa, Chihiro
    Nagai, Yoshiaki
    Hagiwara, Koichi
    Koyama, Shinichiro
    CHEMOTHERAPY, 2017, 62 (03) : 151 - 158
  • [3] Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation
    Ono, A.
    Kenmotsu, H.
    Watanabe, M.
    Serizawa, M.
    Mori, K.
    Imai, H.
    Taira, T.
    Naito, T.
    Murakami, H.
    Nakajima, T.
    Ohde, Y.
    Endo, M.
    Yamamoto, N.
    Koh, Y.
    Takahashi, T.
    ANNALS OF ONCOLOGY, 2014, 25 (10) : 1948 - 1953
  • [4] Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer
    Chen, Zhen
    Zhang, Jing
    Huang, Ke
    Shen, Qian
    Teng, Xiaodong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (09): : 4644 - 4649
  • [5] Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation
    Zhu, Yajie
    Tang, Jianning
    Li, Xin
    Qin, Tian
    Wei, Yang
    ONCOTARGETS AND THERAPY, 2020, 13 : 10447 - 10451
  • [6] L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Takada, Minoru
    Kawahara, Masaaki
    Kitahara, Naoto
    Tanaka, Hisaichi
    Okumura, Meinoshin
    Matsumura, Akihide
    Iuchi, Keiji
    Kawaguchi, Tomoya
    Yukiue, Haruhiro
    Kobayashi, Yoshihiro
    Yano, Motoki
    Fujii, Yoshitaka
    LUNG CANCER, 2006, 54 (01) : 103 - 108
  • [7] Unusual synchronous double primary treatment-naive lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer
    Weng, Ching-Fu
    Chen, Po-Ju
    Tseng, Ailun Heather
    Huang, Shih-Hung
    Lee, Henry Hsin-Chung
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (01)
  • [8] Lung adenocarcinoma harboring rare epidermal growth factor receptor L858R and V834L mutations treated with icotinib: A case report
    Zhai, Shu-Sen
    Yu, Hui
    Gu, Tian-Tian
    Li, Yan-Xia
    Lei, Yan
    Zhang, Hai-Yan
    Zhen, Tong-Huan
    Gao, Yun-Ge
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3841 - 3846
  • [9] Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer
    Ching-Fu Weng
    Po-Ju Chen
    Ailun Heather Tseng
    Shih-Hung Huang
    Henry Hsin-Chung Lee
    World Journal of Surgical Oncology, 17
  • [10] Durable response to afatinib rechallenge in a long-term survivor of non-small cell lung cancer harboring EGFR L858R and L747V mutations
    Kanbe, Mio
    Sunaga, Noriaki
    Hara, Kenichiro
    Sawada, Hiiru
    Wakamatsu, Ikuo
    Hara, Kentaro
    Muto, Sohei
    Sawada, Yuri
    Masubuchi, Hiroaki
    Sato, Mari
    Miura, Yosuke
    Tsurumaki, Hiroaki
    Yatomi, Masakiyo
    Sakurai, Reiko
    Koga, Yasuhiko
    Ohtaki, Yoichi
    Nagashima, Toshiteru
    Okano, Naoko
    Kubo, Nobuteru
    Maeno, Toshitaka
    Hisada, Takeshi
    THORACIC CANCER, 2022, 13 (22) : 3225 - 3228